Shenzhen - Delayed Quote CNY

Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)

51.91
-0.39
(-0.75%)
At close: May 9 at 3:04:46 PM GMT+8
Loading Chart for 300832.SZ
  • Previous Close 52.30
  • Open 52.10
  • Bid 51.95 x --
  • Ask 51.99 x --
  • Day's Range 51.90 - 52.47
  • 52 Week Range 49.01 - 97.20
  • Volume 1,734,684
  • Avg. Volume 3,615,008
  • Market Cap (intraday) 40.787B
  • Beta (5Y Monthly) -0.43
  • PE Ratio (TTM) 22.18
  • EPS (TTM) 2.34
  • Earnings Date Apr 26, 2025
  • Forward Dividend & Yield 1.00 (1.93%)
  • Ex-Dividend Date May 15, 2024
  • 1y Target Est 71.54

Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.

www.snibe.com

2,841

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300832.SZ

View More

Performance Overview: 300832.SZ

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300832.SZ
26.73%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

300832.SZ
31.63%
SSE Composite Index (000001.SS)
5.95%

3-Year Return

300832.SZ
32.66%
SSE Composite Index (000001.SS)
11.25%

5-Year Return

300832.SZ
161.82%
SSE Composite Index (000001.SS)
15.43%

Compare To: 300832.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300832.SZ

View More

Valuation Measures

As of 5/9/2025
  • Market Cap

    40.79B

  • Enterprise Value

    38.31B

  • Trailing P/E

    22.17

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.79

  • Price/Book (mrq)

    4.53

  • Enterprise Value/Revenue

    8.26

  • Enterprise Value/EBITDA

    18.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    39.66%

  • Return on Assets (ttm)

    13.17%

  • Return on Equity (ttm)

    21.68%

  • Revenue (ttm)

    4.64B

  • Net Income Avi to Common (ttm)

    1.84B

  • Diluted EPS (ttm)

    2.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.48B

  • Total Debt/Equity (mrq)

    0.04%

  • Levered Free Cash Flow (ttm)

    410.78M

Research Analysis: 300832.SZ

View More

People Also Watch